ADAP
Adaptimmune Therapeutics
ADAP
ADAP
59 hedge funds and large institutions have $274M invested in Adaptimmune Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
30% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 20
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Holders
59
Holding in Top 10
1
Calls
$85K
Puts
–
Top Buyers
| 1 | +$2.01M | |
| 2 | +$1.68M | |
| 3 | +$1.22M | |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$937K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$302K |
Top Sellers
| 1 | -$5.1M | |
| 2 | -$1.24M | |
| 3 | -$1.2M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$872K |